Results 81 to 90 of about 14,279 (236)
International Journal of COPD, 2020 Yi-Fen Lei,1,2 Hsiu-Chen Lin,3,4 Hsiu-Li Lin,5 Yow-Sheng Uang,2 Hui-Wen Cheng,2 Li-Hsuan Wang2,6 1Department of Pharmacy, Mackay Memorial Hospital, Taipei 10449, Taiwan; 2School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei 11031 ...
Lei YF +5 more
doaj
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims The association between glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) use and the development of bowel obstruction/ileus remains unclear, and evidence for specific bowel obstruction/ileus subtypes remains limited. We examined the association between GLP‐1RA use and the incidence of bowel obstruction/ileus subtypes across different ...
Yuichiro Matsuo +3 more
wiley +1 more source
Chemical degradation kinetics of fibrates: bezafibrate, ciprofibrate and fenofibrate
Brazilian Journal of Pharmaceutical SciencesFibrates are drugs used for the treatment of hypertriglyceridemia and for the prevention of atherosclerosis. Three drugs in the fibrate class, ciprofibrate, fenofibrate and bezafibrate, were chosen for this study because their raw materials are readily ...
Marcelo Antonio de Oliveira +2 more
doaj +1 more source
Therapies for Cardiovascular‐Kidney‐Liver‐Metabolic Syndrome: Reappraisal of Fibrates
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Cardiovascular disease, chronic kidney disease (CKD), type 2 diabetes mellitus (T2DM), obesity and metabolic dysfunction‐associated steatohepatitis (MASH) frequently coexist and share overlapping pathophysiology, forming the proposed cardiovascular‐kidney‐liver‐metabolic (CKLM) syndrome.
Virginia Anagnostopoulou +5 more
wiley +1 more source
Role of fibrates in reducing coronary risk: a UK Consensus
, 2004 This paper presents the consensus reached by a panel of experts on the role of fibrates in reducing coronary heart disease (CHD). The emphasis is on the application of these agents in clinical practice.
Byrne, Christopher D.
core +1 more source
, 2012 The effects of fibrates on C-reactive protein (CRP) are controversial. This meta-analysis was conducted to synthesize the available clinical trial evidence and summarize the effects of fibrates on CRP concentrations.
Yongchen Hao +4 more
core +1 more source
Anti-atherogenic effects of fibrates in type 2 diabetes [PDF]
, 2001 Type 2 diabetes is an increasing cause of premature coronary heart disease. Several trials with lipid-modifying therapy have included sufficient numbers of diabetics to indicate that treatment of diabetic dyslipidaemia with either fibrates or statins ...
Philip Barter +2 more
core +1 more source
Pemafibrate Improves Cholestatic Markers Regardless of the Presence of Primary Biliary Cholangitis
Hepatology Research, EarlyView.Pemafibrate improves liver function markers related to bile flow in primary biliary cholangitis (PBC), but whether this effect is disease‐specific remains unclear. In this study, pemafibrate reduced these markers in patients with and without PBC, suggesting broader effects on bile flow beyond PBC.
Ryohei Tanigawa +5 more
wiley +1 more source
Update on the use of fibrates: focus on bezafibrate
, 2008 Ilan Goldenberg1, Michal Benderly2, Uri Goldbourt2,31Heart Institute and 2Neufeld Cardiac Research Institute, Sheba Medical Center Tel Hashomer, Israel; 3Division of Epidemiology and Preventive Medicine, Sackler School of Medicine, Tel-Aviv University ...
Ilan Goldenberg +2 more
core
Hepatology Research, EarlyView.Impairment of health‐related quality of life in patients with PBC, in particular observed in younger female, represents distinct dimensions of disease impact, independently of long‐term outcomes. Overall and interindividual changes in PBC‐40 scores greatly varied over 10 years, suggesting that symptom burdens are driven by heterogeneous underlying ...
Akihito Takeuchi +22 more
wiley +1 more source